Transfusion Medicine and Hemostasis - 2nd Edition - ISBN: 9780123971647, 9780123977885

Transfusion Medicine and Hemostasis

2nd Edition

Clinical and Laboratory Aspects

Editors: Beth Shaz Christopher Hillyer
eBook ISBN: 9780123977885
Paperback ISBN: 9780123971647
Imprint: Elsevier Science
Published Date: 11th June 2013
Page Count: 1014
Sales tax will be calculated at check-out Price includes VAT/GST
15% off
15% off
15% off
15% off
75.41
64.10
70.95
60.31
56.99
48.44
89.95
76.46
Unavailable
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

The second edition of Transfusion Medicine and Hemostasis continues to be the only "pocket-size" quick reference for pathology residents and transfusion medicine fellows. It covers all topics in blood banking, transfusion medicine, and clinical and laboratory based coagulation. Short, focused chapters, organized by multiple hierarchical headings, are supplemented with up to 10 suggested reading citations. This single reference covers essentially all the topics required to meet the goals and objectives of a major program in transfusion medicine and clinical coagulation.

New chapters in the coagulation testing section reflect the development of new tests available and their incorporation into clinical practice. Coverage includes essential updates on the importance of new cellular therapies, peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in the understanding of molecular testing and pathogen reduction in two separate quality control chapters (one for blood centers and one for hospitals).

Key Features

  • Updated content covers new coagulation tests, cellular therapies, and quality control issues
  • Easy to use, with focused, well-defined chapters in a standardized format throughout
  • Offers quick "cross-reference" lists at the end of each chapter
  • Includes lists of common abbreviations and indexes that cross reference diagnostic, clinical and therapeutic commonalities

Readership

Residents and fellows in hematology, transfusion medicine, pathology, and anesthesiology; practicing physicians in hematology, transfusion medicine, pathology, and anesthesiology.

Table of Contents

TABLE OF CONTENTS:<BR id=""CRLF""><BR id=""CRLF"">I. Blood Banking and Transfusion Medicine<BR id=""CRLF""> <BR id=""CRLF"">A. Introduction<BR id=""CRLF""> <BR id=""CRLF"">1. BLOOD BANKING AND TRANSFUSION MEDICINE – THE FIELD, THE DISCIPLINE AND THE INDUSTRY<BR id=""CRLF"">CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""> <BR id=""CRLF"">2. A BRIEF HISTORY OF BLOOD TRANSFUSION<BR id=""CRLF"">ALFRED J. GRINDON, MD <BR id=""CRLF""><BR id=""CRLF"">3. INTRODUCTION TO QUALITY SYSTEMS and QUALITY MANAGEMENT JIMMIE L. EVANS AND CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">B. Blood Banking<BR id=""CRLF""> <BR id=""CRLF"">4. THE ROLE OF THE PHYSICIAN IN THE BLOOD CENTER<BR id=""CRLF"">CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">a. Donation process<BR id=""CRLF""><BR id=""CRLF"">5. BLOOD DONOR, DONATION PROCESS AND TECHNICAL ASPECTS OF BLOOD COLLECTION<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""> <BR id=""CRLF"">6. APHERESIS BLOOD COMPONENT COLLECTIONS<BR id=""CRLF""> KRISTA L. HILLYER, MD <BR id=""CRLF""> <BR id=""CRLF"">7. RECIPIENT-SPECIFIC BLOOD DONATION<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">8. ADVERSE DONOR REACTIONS<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">b. Component manufacturing<BR id=""CRLF""><BR id=""CRLF"">9. COMPONENT PREPARATION AND MANUFACTURING<BR id=""CRLF"">COURTNEY E. GREENE AND CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">c. Donor testing<BR id=""CRLF""><BR id=""CRLF"">10. SEROLOGIC TESTING OF DONOR PRODUCTS<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">11. OVERVIEW OF INFECTIOUS DISEASE TESTING<BR id=""CRLF"">CHRISTOPHER D. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">12. HIV SCREENING OF DONOR PRODUCTS<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">13. HEPATITIS B SCREENING OF DONOR PRODUCT<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">14. HEPATITIS C SCREENING OF DONOR PRODUCT<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">15. WNV SCREENING OF DONOR PRODUCT<BR id=""CRLF"">KRISTA L. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">16. SYPHILIS, HTLV, AND CHAGAS TESTING OF DONOR PRODUCT<BR id=""CRLF"">CHELSEA A. SHEPPARD, MD AND KRISTA L. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">17. BACTERIAL DETECTION METHODS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">C. Transfusion Medicine<BR id=""CRLF""> <BR id=""CRLF"">18. THE ROLE OF THE TRANSFUSION SERVICE PHYSICIAN<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">a. Testing<BR id=""CRLF""><BR id=""CRLF"">19. PRETRANSFUSION TESTING<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">20. ANTIBODY IDENTIFICATION<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">21. DIRECT ANTIGLOBULIN TEST<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">b. Blood groups<BR id=""CRLF""><BR id=""CRLF"">22. ABO AND H BLOOD GROUP SYSTEMS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">23. RH BLOOD GROUP SYSTEM<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">24. KELL AND KIDD BLOOD GROUP SYSTEMS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">25. MNS AND DUFFY BLOOD GROUP SYSTEMS<BR id=""CRLF"">BETH H. SHAZ, MD JOHN D. ROBACK, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">26. LEWIS,I , AND P BLOOD GROUP SYSTEMS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">27. OTHER BLOOD GROUP SYSTEMS, COLLECTIONS, AND ANTIGENS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">c. Blood products<BR id=""CRLF""><BR id=""CRLF"">28. RED BLOOD CELLS AND RELATED PRODUCTS<BR id=""CRLF"">CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">29. PLASMA PRODUCTS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">30. PLATELET PRODUCTS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">31. CRYOPRECIPITATE<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">32. GRANULOCYTE PRODUCTS<BR id=""CRLF"">CHRISTOPHER D. HILLYER, MD AND LAWRENCE B. FIALCOW, DO <BR id=""CRLF"">33. ALBUMIN AND RELATED PRODUCTS<BR id=""CRLF"">ANNE M. WINKLER, MD AND BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">34. HUMAN IMMUNOGLOBULIN PREPARATIONS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">35. RH IMMUNE GLOBULIN<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">d.Product modifications<BR id=""CRLF""><BR id=""CRLF"">36. IRRADIATION OF BLOOD PRODUCTS<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">37. LEUKOREDUCTION OF BLOOD PRODUCTS<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">38. CMV- SAFE BLOOD PRODUCTS<BR id=""CRLF"">JOHN D. ROBACK, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">39. FROZEN BLOOD PRODUCTS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD and BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">40. WASHED BLOOD PRODUCTS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD and BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">41. VOLUME REDUCED BLOOD PRODUCTS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">e. Specific clinical settings<BR id=""CRLF""><BR id=""CRLF"">42. NEONATAL AND PEDIATRIC TRANSFUSION MEDICINE<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD AND CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">43. PERINATAL TRANSFUSION MEDICINE<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">44. AUTOIMMUNE HEMOLYTIC ANEMIAS<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">45. TRANSFUSION MANAGEMENT IN PATIENTS WITH HEMOGLOBINOPATHIES<BR id=""CRLF""> BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">46. TRANSFUSION OF PATIENTS UNDERGOING HPC AND SOLID ORGAN TRANSPLANTATION<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">47. TRANSFUSION OF HIV POSITIVE PATIENTS<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">48. TRANSFUSION MANAGEMENT IN PATIENTS WHO REFUSE BLOOD TRANSFUSION<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD AND JOHN D. ROBACK, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">49. PLATELET TRANSFUSION REFRACTORY PATIENTS<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD and JOHN D. ROBACK, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">50. MASSIVE TRANSFUSION<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">51. PERIOPERATIVE BLOOD MANAGEMENT<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">f. Transfusion reactions<BR id=""CRLF""><BR id=""CRLF"">52. ADVERSE EVENTS AND OUTCOMES FOLLOWING TRANSFUSION: AN OVERVIEW<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">53. FEBRILE NON-HEMOLYTIC TRANSFUSION REACTIONS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">54. ALLERGIC, ANAPHYLACTOID AND ANAPHYLATIC REACTIONS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">55. ACUTE HEMOLYTIC TRANSFUSION REACTIONS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">56. DELAYED HEMOLYTIC TRANSFUSION REACTIONS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">57. TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">58. TRANSFUSION RELATED ACUTE LUNG INJURY<BR id=""CRLF"">JEANNE E. HENDRICKSON, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">59. SEPTIC TRANSFUSION REACTIONS<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">60. METABOLIC, HYPOTENSIVE AND OTHER ACUTE REACTIONS AND COMPLICATIONS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">61. POST TRANSFUSION PURPURA<BR id=""CRLF"">ALFRED J. GRINDON<BR id=""CRLF""><BR id=""CRLF"">62. TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD<BR id=""CRLF""><BR id=""CRLF"">63. MICROCHIMERISM<BR id=""CRLF"">BETH H. SHAZ, MD and CHRISTOPHER D. HILLYER, MD <BR id=""CRLF""><BR id=""CRLF"">64. TRANSFUSION RELATED IMMUNOMODULATION<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">65. IRON OVERLOAD<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">66. TRANSFUSION TRANSMITTED DISEASES<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">g. Therapeutic apheresis and phlebotomy<BR id=""CRLF""><BR id=""CRLF"">67. OVERVIEW TO THERAPEUTIC APHERESIS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""> <BR id=""CRLF"">68. THERAPEUTIC PLASMA EXCHANGE<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">69. THERAPEUTIC ERYTHROCYTAPHERESIS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">70. THERAPEUTIC THROMBOCYTAPHERESIS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">71. THERAPEUTIC LEUKOCYTAPHERESIS<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">72. EXTRACORPOREAL PHOTOPHERESIS<BR id=""CRLF"">MARY DORROW, MD JEANNE E. HENDRICKSON, MD, and JOHN D. ROBACK, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">73. LDL APHERESIS<BR id=""CRLF"">BETH H. SHAZ, MD<BR id=""CRLF""><BR id=""CRLF"">74. IMMUNOABSORPTION<BR id=""CRLF"">BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">75. THERAPEUTIC PHLEBOTOMY<BR id=""CRLF"">LAWRENCE B. FIALCOW, DO and BETH H. SHAZ, MD <BR id=""CRLF""><BR id=""CRLF"">h. Cellular therapy and tissue banking<BR id=""CRLF""><BR id=""CRLF"">76. HPC PRODUCTS<BR id=""CRLF"">JOHN D. ROBACK, MD, PhD and ELLIE HAMILTON <BR id=""CRLF""><BR id=""CRLF"">77. TISSUE BANKING in the HOSPITAL SETTING<BR id=""CRLF"">CASSSANDRA D. JOSEPHSON, MD <BR id=""CRLF""><BR id=""CRLF"">II. Coagulation<BR id=""CRLF""><BR id=""CRLF"">A. Introduction<BR id=""CRLF""><BR id=""CRLF"">78. AN OVERVIEW OF THE COAGULATION SYSTEM<BR id=""CRLF"">THOMAS C. ABSHIRE, MD and SHAWN JOBE, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">B. Clinical coagulation<BR id=""CRLF""><BR id=""CRLF"">79. APPROACH TO THE BLEEDING PATIENT<BR id=""CRLF"">THOMAS C. ABSHIRE, MD <BR id=""CRLF""><BR id=""CRLF"">a. Neonatal thrombocytopenia<BR id=""CRLF""><BR id=""CRLF"">80. CONGENITAL THROMBOCYTOPENIA <BR id=""CRLF"">SHAWN JOBE, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">81. NEONATAL ALLOIMMUNE THROMBOCYTOPENIA<BR id=""CRLF"">CAROLYN BENNETT, MD<BR id=""CRLF""><BR id=""CRLF"">82. ACQUIRED NEONATAL THROMBOCYTOPENIA<BR id=""CRLF"">CAROLYN BENNETT, MD <BR id=""CRLF""><BR id=""CRLF"">b. inherited platelet function disorders<BR id=""CRLF""><BR id=""CRLF"">83. BERNARD-SOULIER SYNDROME AND OTHER GPIB-IX-V RELATED RECEPTOR DEFECTS<BR id=""CRLF"">SHAWN JOBE, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">84. GLANZMANN'S THROMBOCYTOPENIA<BR id=""CRLF"">SHAWN JOBE, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">85. PLATELET STORAGE GRANULE DEFECTS<BR id=""CRLF"">SHAWN JOBE, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">86. FAILURE TO RELEASE AND ASPIRIN-LIKE DEFECTS<BR id=""CRLF"">SHAWN JOBE, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">c. Immune thrombocytopenia <BR id=""CRLF""><BR id=""CRLF"">87. ACUTE (CHILDHOOD) IMMUNE THROMBOCYTOPENIC PURPURA CAROLYN BENNETT, MD<BR id=""CRLF""> <BR id=""CRLF"">88. CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA<BR id=""CRLF"">CAROLYN BENNETT, MD <BR id=""CRLF""><BR id=""CRLF"">89. DRUG INDUCED THROMBOCYTOPENIA<BR id=""CRLF"">CAROLYN BENNETT, MD<BR id=""CRLF""><BR id=""CRLF"">90. HEPARIN INDUCED THROMBOCYTOPENIA<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">91. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME<BR id=""CRLF"">MICHAEL BRIONES, DO<BR id=""CRLF""><BR id=""CRLF"">d. Immune mediated coagulopathies<BR id=""CRLF""><BR id=""CRLF"">92. HEMOLYTIC UREMIC SYNDROME<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">93. THROMBOTIC THROMBOCYTOPENIC PURPURA<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">94. ANTIPHOSPHOLIPID ANTIBODY SYNDROME<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">e. congenital bleeding disorders<BR id=""CRLF""><BR id=""CRLF"">95. VON WILLEBRAND DISEASE<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">96. HEMOPHILIA A<BR id=""CRLF"">AMY DUNN, MD <BR id=""CRLF""><BR id=""CRLF"">97. HEMOPHILIA B<BR id=""CRLF"">AMY DUNN, MD <BR id=""CRLF""><BR id=""CRLF"">98. CONGENITAL DISORDERS OF FIBRINOGEN<BR id=""CRLF"">SHANNON MEEKS, MD <BR id=""CRLF""><BR id=""CRLF"">99. FACTOR XIII, D á2-ANTIPLASMIN, AND PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCIES<BR id=""CRLF"">SHANNON MEEKS, MD <BR id=""CRLF""><BR id=""CRLF"">100. FACTOR XI DEFICIENCY<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">101. FACTOR VII DEFICIENCY<BR id=""CRLF"">SHANNON MEEKS, MD <BR id=""CRLF""><BR id=""CRLF"">102. FACTOR II, FACTOR V, AND FACTOR X DEFICIENCIES<BR id=""CRLF"">SHANNON MEEKS, MD <BR id=""CRLF""><BR id=""CRLF"">f. acquired bleeding disorders<BR id=""CRLF""><BR id=""CRLF"">103. BLEEDING DISORDERS IN PREGNANCY<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">104. VASCULAR BLEEDING DISORDERS<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">105. BLEEDING RISKS WITH LIVER DISEASE<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">106. BLEEDING RISKS WITH VITAMIN K DEFICIENCY<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">107. BLEEDING RISKS WITH CARDIAC DISEASE<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">108. BLEEDING RISKS WITH RENAL DISEASE<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">109. BLEEDING IN CANCER<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">110. DISSEMINATED INTRAVASCULAR COAGULOPATHY<BR id=""CRLF"">AMY DUNN, MD <BR id=""CRLF""><BR id=""CRLF"">111. ACQUIRED COAGULATION FACTOR INHIBITORS<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">C. Laboratory testing of coagulation<BR id=""CRLF""><BR id=""CRLF"">a. Introduction<BR id=""CRLF""> <BR id=""CRLF"">112. INTRODUCTION TO COAGULATION TESTING<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">b. Screening tests<BR id=""CRLF""><BR id=""CRLF"">113. PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">114. PLATELET COUNT<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">115. GLOBAL TESTS FOR PRIMARY HEMOSTASIS<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">c. Laboraty assessment of platelet disorders<BR id=""CRLF""><BR id=""CRLF"">116. PLATELET AGGREGATION STUDIES<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">117. LABORATORY DIAGNOSIS OF GENETIC PLATELET FUNCTION DEFECTS<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">118. LABORATORY DIAGNOSIS OF ACQUIRED PLATELET FUNCTION DEFECTS<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">119. LABORATORY DIAGNOSIS IMMUNE THROMBOCYTOPENIC PURPURA<BR id=""CRLF"">CAROLYN BENNETT, MD<BR id=""CRLF""><BR id=""CRLF"">120. ADAMTS 13 ASSAYS<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">121. LABORATORY TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA<BR id=""CRLF"">ANNE M. WINKLER, MD AND JAMES C. ZIMRING, MD, PHD<BR id=""CRLF""><BR id=""CRLF"">d. Laboratoy assessment of VWD<BR id=""CRLF""><BR id=""CRLF"">122. MOLECULAR BIOLOGY OF VON WILLEBRAND DISEASE<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">123. DIAGNOSIS OF INHERITED VON WILLEBRAND DISEASE<BR id=""CRLF"">Connie H. Miller Ph.D.<BR id=""CRLF""><BR id=""CRLF"">124. LABORATORY DIAGNOSIS OF ACQUIRED VWD<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">125. LABORATORY ASSESSMENT OF TREATMENT OF VWD<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">e. Laboratoy assessment of coagulation factor disorders<BR id=""CRLF""><BR id=""CRLF"">126. SPECIFIC FACTOR ASSAYS<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">127. MIXING STUDIES<BR id=""CRLF"">CONNIE H. MILLER Ph.D.<BR id=""CRLF""><BR id=""CRLF"">128. SPECIFIC FACTOR INHIBITORS<BR id=""CRLF"">Connie H. Miller Ph.D.<BR id=""CRLF""><BR id=""CRLF"">f. Laboratoy assessment of fibrinogen and fibrinolysis<BR id=""CRLF""><BR id=""CRLF"">129. LABORATORY DIAGNOSIS OF DYSFIBRINOGENEMIA AND AFIBRINOGENEMIA<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">130. LABORATORY ASSESSMENT OF FIBRINOLYSIS<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">g. Tests for hypercoagulable state<BR id=""CRLF""><BR id=""CRLF"">131. GENERAL OVERVIEW OF THE HYPERCOAGULABLE STATE<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">132. ANTITHROMBIN TESTING<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">133. PROTEINS C, S, AND Z<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">134. ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN<BR id=""CRLF"">ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">135. PROTHROMBIN GENE MUTATION<BR id=""CRLF"">ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD <BR id=""CRLF""><BR id=""CRLF"">136. HYPERHOMOCYSTENEMIA<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">137. LUPUS ANTICOAGULANT AND ANTIPHOSPHOLIPID ANTIBODIES<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">138. LIPOPROTEIN (A)<BR id=""CRLF"">ANNE M. WINKLER MD and JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">139. FACTOR LEVEL ABNORMALITIES ASSOCIATED WITH THROMBOSIS<BR id=""CRLF"">JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">h. Tests for activation of the coagulation system<BR id=""CRLF""><BR id=""CRLF"">140. LABORATORY MANAGEMENT OF DIC<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">i. Laboratoy support for anticoagulation<BR id=""CRLF""><BR id=""CRLF"">141. HEPARIN MONITORING<BR id=""CRLF"">ANNE WINKLER MD AND JAMES C. ZIMRING, MD, PhD<BR id=""CRLF""><BR id=""CRLF"">142. WARFARIN MONITORING<BR id=""CRLF"">ANNE M. WINKLER M.D.<BR id=""CRLF""><BR id=""CRLF"">D. Coagulation factor products<BR id=""CRLF""><BR id=""CRLF"">143. PROTHROMBIN COMPLEX CONCENTRATES<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">144. VON WILLEBRAND FACTOR PRODUCTS<BR id=""CRLF"">THOMAS C. ABSHIRE, MD<BR id=""CRLF""><BR id=""CRLF"">145. FACTOR VIII CONCENTRATES<BR id=""CRLF"">AMY DUNN, MD <BR id=""CRLF""><BR id=""CRLF"">146. FACTOR IX CONCENTRATES<BR id=""CRLF"">AMY DUNN, MD <BR id=""CRLF""><BR id=""CRLF"">147. FACTOR VII CONCENTRATE<BR id=""CRLF"">CHRISTINE KEMPTON, MD<BR id=""CRLF""><BR id=""CRLF"">148. ANTITHROMBIN PRODUCTS<BR id=""CRLF"">MICHAEL BRIONES, DO <BR id=""CRLF""><BR id=""CRLF"">149. PROTEIN C PRODUCTS<BR id=""CRLF"">MICHAEL BRIONES, DO

Details

No. of pages:
1014
Language:
English
Copyright:
© Elsevier Science 2013
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780123977885
Paperback ISBN:
9780123971647

About the Editor

Beth Shaz

Chief Medical Officer and Vice President of Medical Programs and Services, New York Blood Center, New York, NY; Clinical Assistant Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA. Dr. Shaz is a member of the Board of Directors of AABB and the American Society for Apheresis. She is an associate editor for Transfusion and on the editorial board of the Journal of Clinical Apheresis.

Affiliations and Expertise

Chief Medical Officer and Vice President of Medical Programs and Services, New York Blood Center, New York, NY, USA

Christopher Hillyer

Professor of Medicine, Cornell Weill Medical College, New York, NY. Dr. Hillyer also is the immediate past-president of the American Association of Blood Banking and a trustee of the National Blood Foundation (NBF). He is an associate editor of Transfusion and serves on several other editorial boards including Blood.

Affiliations and Expertise

President and CEO, New York Blood Center, New York, NY, USA

Reviews

"This book truly covers both hemostasis and transfusion medicine and bridges seamlessly between the disciplines, laboratory science, diagnosis (including clinical features), and medical treatment...Each chapter is so well contained and informative, it is like a tempting one-bite appetizer suitable for measured ingestion according to a reader's appetite for and ability to retain new information."--Doody.com, October 4, 2013
"Shaz, Hillyer, Roshal, and Abrams…provide clinical and laboratory information in transfusion medicine and hemostasis for all physicians and allied health professionals who order and administer blood components and specialized factors for hemostatic abnormalities in patients, as well as those who consult and care for these patients."--Reference and Research Book News, August 2013

Ratings and Reviews